Compare EWTX & MMSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EWTX | MMSI |
|---|---|---|
| Founded | 2017 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.1B |
| IPO Year | 2021 | 1996 |
| Metric | EWTX | MMSI |
|---|---|---|
| Price | $44.40 | $86.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $39.00 | ★ $98.88 |
| AVG Volume (30 Days) | ★ 923.8K | 588.5K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 4.93 |
| EPS | N/A | ★ 1.33 |
| Revenue | N/A | ★ $1,515,906,000.00 |
| Revenue This Year | N/A | $8.85 |
| Revenue Next Year | N/A | $5.88 |
| P/E Ratio | ★ N/A | $65.56 |
| Revenue Growth | N/A | ★ 11.75 |
| 52 Week Low | $13.69 | $59.74 |
| 52 Week High | $48.40 | $94.75 |
| Indicator | EWTX | MMSI |
|---|---|---|
| Relative Strength Index (RSI) | 51.19 | 45.25 |
| Support Level | $41.31 | $82.68 |
| Resistance Level | $46.26 | $92.22 |
| Average True Range (ATR) | 1.92 | 1.87 |
| MACD | -0.16 | -1.05 |
| Stochastic Oscillator | 44.89 | 15.88 |
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.